Prices are updated after-hours

Health Technology Nasdaq

9 Meters Biopharma, Inc.

NMTR | $0.0722 -42.97% -67.9% 10M

(0.0% 1d) (0.0% 1m) (-93.1% 1y) (0.0% 2d) (0.0% 3d) (-43.0% 7d) (254.86% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 1,043,990
http://www.innovatebiopharma.com
Sec Filling | Patents | 8 employees

(US) 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

autoimmunity

add to watch list Paper trade email alert is off

Abcam plc

ABCM | News | $23.99 0.0% 7.4M

Health Technology

(0.0% 1d) (0.0% 1m) (54.6% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 5,500,233,049
http://abcam.com
Sec Filling | Patents | 1500 employees

Abcam Plc distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. The company was founded by Adam Robert David Cleevely, Anthony Kouzarides and Jonathan Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.

antibody

add to watch list Paper trade email alert is off

ABIOMED, Inc.

ABMD | $381.02 0.06% 0.07%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (758.37% volume)
Earnings Calendar: 2023-02-02
Market Cap: $ 17,180,642,928
http://www.abiomed.com
Sec Filling | Patents | 1536 employees

(US) ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.

heart brands

add to watch list Paper trade email alert is off

Acer Therapeutics Inc.

ACER | $0.9 -3.61% 420K

Health Technology

(0.0% 1d) (0.0% 1m) (3.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees

(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.

acquisitions urine urea treatment

add to watch list Paper trade email alert is off

Adamis Pharmaceuticals Corporation

ADMP | $0.7751 0.86% 2.6% 120K

Health Technology

(0.0% 1d) (0.0% 1m) (-87.2% 1y) (0.0% 2d) (0.9% 3d) (0.0% 7d) (20.14% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 7,254,264
http://www.adamispharmaceuticals.com
Sec Filling | Patents | 171 employees

(US) Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.

respiratory opioid

add to watch list Paper trade email alert is off

Aerie Pharmaceuticals, Inc.

AERI | $15.25 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees

(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

eye treatment

Drugs

Rhopressa (netarsudil)
Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

add to watch list Paper trade email alert is off

CymaBay Therapeutics Inc.

CBAY | $32.48 0.03% 8.4M

Health Technology

(0.0% 1d) (0.0% 1m) (229.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-56.22% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 3,726,247,895
http://www.cymabay.com
Sec Filling | Patents | 60 employees

(US) CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

education liver liver disease

add to watch list Paper trade email alert is off

Diffusion Pharmaceuticals Inc.

DFFN 4 | $6.6 11.68% -34.32% 350K

Health Technology

(0.0% 1d) (0.0% 1m) (15.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (308.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 13,465,894
http://www.diffusionpharma.com
Sec Filling | Patents | 10 employees

(US) Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

treatment

add to watch list Paper trade email alert is off

Eargo, Inc.

EAR | $2.57 7.78% 200K

Health Technology

(0.0% 1d) (0.0% 1m) (-46.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2984.13% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 53,385,286
http://www.eargo.com
Sec Filling | Patents | 239 employees

Eargo, Inc. develops next generation hearing aids and headsets solutions. It offers Eargomax, a new chip for maximum audio fidelity and noise reduction and Eargoplus a superior hearing technology designed for first time hearing aid users. The company was founded by Florent Michel, Raphael Michel and Daniel Shen on November 12, 2010 and is headquartered in San Jose, CA.

audio chip

add to watch list Paper trade email alert is off

Endo International plc

ENDP | News | $0.2926 -9.6%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

cardiovascular women health nervous system women brands msa injection

add to watch list Paper trade email alert is off

Entasis Therapeutics Holdings Inc.

ETTX | $2.19 -0.46% 0.46%

Health Technology

(0.0% 1d) (-0.2% 1m) (0.0% 1y) (-0.2% 2d) (0.2% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-08-03
Market Cap: $ 104,795,396
http://www.entasistx.com
Sec Filling | Patents | 47 employees

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

batteries battery msa antibacterial injection

add to watch list Paper trade email alert is off

Epizyme, Inc.

EPZM | $1.47 -1.34% 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-1.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2022-08-08
Market Cap: $ 247,496,185
http://www.epizyme.com
Sec Filling | Patents | 203 employees

(US) Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

cancer ovarian cancer t-cell lungs genetic leukemia ceiling

Drugs

TAZVERIK (tazemetostat)

add to watch list Paper trade email alert is off

Evelo Biosciences, Inc.

EVLO | $0.3165 -87.39% 710K

Health Technology

(0.0% 1d) (0.0% 1m) (-89.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-17.9% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 6,008,068
http://www.evelobio.com
Sec Filling | Patents | 98 employees

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

cancer msa treatment

add to watch list Paper trade email alert is off

Bellicum Pharmaceuticals, Inc.

BLCM | $0.0748 381.28% 6.1K

Health Technology

(0.0% 1d) (0.0% 1m) (-77.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees

(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

cancer immunotherapy

add to watch list Paper trade email alert is off

BELLUS Health Inc.

BLU | $14.74 0.03% 0

Health Technology

(0.0% 1d) (0.0% 1m) (1.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (688.59% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 1,869,211,386
http://www.bellushealth.com
Sec Filling | Patents | 40 employees

(CA) BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

chronic cough hypersensitisation treatment

add to watch list Paper trade email alert is off

Brickell Biotech, Inc.

BBI | $2.12 16.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees

(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

dermatitis skin t-cell treatment ceiling

add to watch list Paper trade email alert is off

Cardiovascular Systems, Inc.

CSII | $20.0 -0.05% 400K

Health Technology

(0.0% 1d) (0.0% 1m) (0.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (22.61% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 843,960,960
http://www.csi360.com
Sec Filling | Patents | 779 employees

(US) Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The firm's products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 1989 and is headquartered in St. Paul, MN.

cardiovascular

add to watch list Paper trade email alert is off

Allena Pharmaceuticals, Inc.

ALNA | $0.075 -12.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (431.58% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 9,156,242
http://www.allenapharma.com
Sec Filling | Patents | 83 employees

(United States) Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

kidney diseases kidney stones treatment kidney

add to watch list Paper trade email alert is off

Allied Healthcare Products, Inc.

AHPI | $0.5501 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.19% volume)
Earnings Calendar:
Market Cap: $ 2,207,847
http://www.alliedhpi.com
Sec Filling | Patents | 218 employees

Allied Healthcare Products, Inc. manufactures, markets, and distributes a variety of respiratory products used in the health care industry to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, and emergency medical product dealers. Its products include respiratory care products, medical gas equipment, and emergency medical products. The company was founded in 1979 and is headquartered in St. Louis, MO.

respiratory construction

add to watch list Paper trade email alert is off

Amryt Pharma plc

AMYT | News | $14.7 0.0% 2.4M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 940,255,350
http://amrytpharma.com
Sec Filling | Patents | n/a employees

Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group’s two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.

treatment